Top 10 US Tech Accelerators

Techstars has funded over 3,800 companies across 50+ accelerator programs worldwide, with portfolio companies raising $34B+ in follow-on funding. Its three-month mentorship-driven model operates in partnership with corporations like Microsoft, Amazon, and Barclays, blending startup speed with enterprise resources. The 2025 Techstars Boston cohort saw an 88% post-program fundraising rate, demonstrating its continued deal-flow quality despite a tighter VC market.

500 Global manages $2.7B in AUM and has invested in over 5,000 companies across 80+ countries, making it one of the world's most geographically diverse early-stage funds. Its flagship accelerator program in San Francisco provides $150K for 6% equity, complemented by a global scout network that surfaces founders in emerging markets. Portfolio exits include Credit Karma ($7.1B), Grab ($40B IPO), and Canva ($40B valuation), validating the global-first thesis.

Andreessen Horowitz manages $35B+ in AUM across nine funds, operating an integrated accelerator-plus-mega-fund model that supports portfolio companies from pre-seed through IPO. Its portfolio includes GitHub ($7.5B), Lyft, Slack, and Airbnb, with recent focus on AI, crypto, and bio. The a16z American Dynamism fund, launched in 2023, targets defense tech and industrial software — a category generating $2B+ in new portfolio value by 2025.

First Round Capital manages $3B+ in AUM and has backed over 300 companies at seed stage, including Uber ($70B+ IPO), Square, Warby Parker, and Notion. Its portfolio community platform connects 3,000+ founders, executives, and operators — a proprietary network effect that drives deal quality. The firm's 2025 cohort averaged a $15M Series A within nine months of first check, outpacing industry median significantly.

IndieBio, operated by SOSV with $380M in AUM, is the world's leading biotech accelerator, funding 200+ life science companies since 2014 including Geltor, Memphis Meats (UPSIDE Foods), and Prellis Biologics. Each cohort receives $250K for a lab bench and six months of intensive mentorship from leading biotech scientists and investors. The 2025 cohort achieved a 78% rate of follow-on funding, reinforcing IndieBio's reputation as the premier gateway to Series A biotech capital.

Plug and Play Tech Center runs the world's largest corporate innovation platform, accelerating over 2,000 startups per year across 50+ industry verticals and 60+ global locations. Its Sunnyvale campus alone has hosted $9B+ in portfolio exits since 1998, including PayPal, Dropbox, and Lending Club as early tenants. The 2025 corporate partner network spans 500+ Fortune 500 companies actively scouting for pilot partnerships through its program cohorts.

MassChallenge operates the world's largest equity-free accelerator, awarding $3M+ in cash prizes annually to startups in Boston, Switzerland, Israel, Mexico, and Rhode Island. Its 2,000+ alumni have raised $9B+, generated $3B+ in revenue, and created 80,000+ jobs, demonstrating that the no-equity model attracts high-quality diverse founders. The 2024 HealthTech cohort included 40 companies targeting AI-assisted diagnostics and chronic disease management, reflecting its sector-specific expansion strategy.

LAUNCH Accelerator, founded by veteran angel investor Jason Calacanis, has invested in 200+ companies since 2012 including Thumbtack, Calm, and Robinhood during seed stages. The program combines $100K–$500K checks with access to Calacanis's 500,000-person podcast audience and prolific angel syndicate. Its 2025 cohort raised an average $4.2M in post-demo funding within 90 days, validating the media-amplified deal model pioneered by LAUNCH.

HAX, operated by SOSV with $500M in AUM, is the world's top hardware and deep tech accelerator, funding 200+ companies across San Francisco and Shenzhen manufacturing facilities. Its portfolio includes Desktop Metal ($1.5B SPAC), Bitfinder, and Makeblock, spanning industrial IoT, robotics, and medical devices. The Shenzhen prototyping facility gives HAX founders a 6-week supply chain sprint unavailable at any other US-based accelerator, compressing hardware development cycles from 18 months to under six.

Techstars has funded over 3,800 companies across 50+ accelerator programs worldwide, with portfolio companies raising $34B+ in follow-on funding. Its three-month mentorship-driven model operates in partnership with corporations like Microsoft, Amazon, and Barclays, blending startup speed with enterprise resources. The 2025 Techstars Boston cohort saw an 88% post-program fundraising rate, demonstrating its continued deal-flow quality despite a tighter VC market.

500 Global manages $2.7B in AUM and has invested in over 5,000 companies across 80+ countries, making it one of the world's most geographically diverse early-stage funds. Its flagship accelerator program in San Francisco provides $150K for 6% equity, complemented by a global scout network that surfaces founders in emerging markets. Portfolio exits include Credit Karma ($7.1B), Grab ($40B IPO), and Canva ($40B valuation), validating the global-first thesis.

Andreessen Horowitz manages $35B+ in AUM across nine funds, operating an integrated accelerator-plus-mega-fund model that supports portfolio companies from pre-seed through IPO. Its portfolio includes GitHub ($7.5B), Lyft, Slack, and Airbnb, with recent focus on AI, crypto, and bio. The a16z American Dynamism fund, launched in 2023, targets defense tech and industrial software — a category generating $2B+ in new portfolio value by 2025.

First Round Capital manages $3B+ in AUM and has backed over 300 companies at seed stage, including Uber ($70B+ IPO), Square, Warby Parker, and Notion. Its portfolio community platform connects 3,000+ founders, executives, and operators — a proprietary network effect that drives deal quality. The firm's 2025 cohort averaged a $15M Series A within nine months of first check, outpacing industry median significantly.

IndieBio, operated by SOSV with $380M in AUM, is the world's leading biotech accelerator, funding 200+ life science companies since 2014 including Geltor, Memphis Meats (UPSIDE Foods), and Prellis Biologics. Each cohort receives $250K for a lab bench and six months of intensive mentorship from leading biotech scientists and investors. The 2025 cohort achieved a 78% rate of follow-on funding, reinforcing IndieBio's reputation as the premier gateway to Series A biotech capital.

Plug and Play Tech Center runs the world's largest corporate innovation platform, accelerating over 2,000 startups per year across 50+ industry verticals and 60+ global locations. Its Sunnyvale campus alone has hosted $9B+ in portfolio exits since 1998, including PayPal, Dropbox, and Lending Club as early tenants. The 2025 corporate partner network spans 500+ Fortune 500 companies actively scouting for pilot partnerships through its program cohorts.

MassChallenge operates the world's largest equity-free accelerator, awarding $3M+ in cash prizes annually to startups in Boston, Switzerland, Israel, Mexico, and Rhode Island. Its 2,000+ alumni have raised $9B+, generated $3B+ in revenue, and created 80,000+ jobs, demonstrating that the no-equity model attracts high-quality diverse founders. The 2024 HealthTech cohort included 40 companies targeting AI-assisted diagnostics and chronic disease management, reflecting its sector-specific expansion strategy.

LAUNCH Accelerator, founded by veteran angel investor Jason Calacanis, has invested in 200+ companies since 2012 including Thumbtack, Calm, and Robinhood during seed stages. The program combines $100K–$500K checks with access to Calacanis's 500,000-person podcast audience and prolific angel syndicate. Its 2025 cohort raised an average $4.2M in post-demo funding within 90 days, validating the media-amplified deal model pioneered by LAUNCH.

HAX, operated by SOSV with $500M in AUM, is the world's top hardware and deep tech accelerator, funding 200+ companies across San Francisco and Shenzhen manufacturing facilities. Its portfolio includes Desktop Metal ($1.5B SPAC), Bitfinder, and Makeblock, spanning industrial IoT, robotics, and medical devices. The Shenzhen prototyping facility gives HAX founders a 6-week supply chain sprint unavailable at any other US-based accelerator, compressing hardware development cycles from 18 months to under six.